Mr. Daly is a biopharmaceutical executive with 30 years of experience leading U.S. and global businesses. He was most recently Chief Commercial Officer of Incyte, a publicly traded oncology and inflammation company. Prior to this, Mr. Daly held multiple leadership positions at Amgen, including his last role as Senior Vice President for North America Commercial Operations.

Before Amgen, he was at GlaxoSmithKline for nearly 17 years where he held various positions in both the U.S. and abroad, including Senior Vice President of the Respiratory Division with responsibility for sales, marketing and medical affairs. Mr. Daly currently serves as a Director at Acadia Pharmaceuticals, Halozyme Therapeutics, Bellicum Pharmaceuticals and Madrigal Pharmaceuticals. He holds a Bachelor of Science in Pharmacy and a Master of Business Administration from the University at Buffalo, New York.

Dr. Read is an entrepreneur and venture investor based in the San Francisco Bay Area with a long track record of building companies that have commercialized important medicines and life-science technologies. From 2000 to 2008, he served as managing director of Alloy Ventures, an early-stage firm investing in life science and technology companies. He is currently is a Venture Partner with the US office for Brandon Capital Partners, the leading life science venture investor in Australia and New Zealand.

Previously, Dr. Read founded Affymax NV where he served as Managing Director and President of the Pharma Division, sold to Glaxo SmithKline and resulted in spin outs of Affymetrix and Maxygen. He was the founding investor, Chairman and CEO of Aviron which developed FluMist™, the intranasal influenza vaccine acquired by MedImmune. Dr. Read has been a director of companies ranging from biotechnology, medical devices, materials science, energy and software.

Dr. Read received a BSc from Rice University in Houston, an MD from the University of Texas Health Science Center at San Antonio, and completed internal medicine training at Duke and the Peter Bent Brigham Hospital, where he held appointments at the Harvard Medical School and School of Public Health. He produced a successful interactive game in 1984 to promote healthy lifestyles and co-authored Total Engagement: Using Games and Virtual Worlds to Change the Way People Work and Businesses Compete (Harvard Business Press, 2009). Dr. Read serves as a director of Allay Therapeutics, Glyscend Therapeutics, Global Kineticw and BioVentures for Global Health. His awards include several as co-inventor of technology underlying the Affymetrix GeneChip™ and Ernst & Young’s Northern California Life Science Entrepreneur of the Year.

Mr. Russell is a veteran in the global biopharmaceutical industry with more than 30 years of experience in senior executive roles leading commercial execution, operations, and strategic acquisitions.

Mr. Russell served as the Chief Executive Officer of Shire plc (SHPG), a biopharmaceutical company, from June 2008 to April 2013. Mr. Russell served as the Chief Financial Officer of Shire from 1999 to 2008 and also served as its Principal Accounting Officer and Executive Vice President of Global Finance. Prior to joining Shire, Mr. Russell served at ICI, Zeneca, and AstraZeneca for 19 years, most recently as Vice President of Corporate Finance at AstraZeneca plc (AZN). Mr. Russell serves as Chairman of the Board of Directors of Revance Therapeutics, Inc. (RVNC) and also serves on the Board of Directors of Lineage Cell Therapeutics, Inc. (LCTX). Mr. Russell holds an honorary Doctor of Business Administration from Coventry University, U.K.

Mr. Welch has spent his career of forty years in the business of developing medicines in both biotech and multi-national pharmaceutical companies. He has had an executive leadership or board director role in developing and/or commercializing over a dozen breakthrough medicines for patients with HIV, multiple sclerosis, cardiovascular disease, cancer and several rare diseases.

Mr. Welch served in several leadership positions, among them: various roles at Sanofi, a leading multinational company, including VP of Global Marketing in Paris and COO of the US business; President of Elan Pharmaceuticals; CEO and Chairman of Triangle Pharmaceuticals acquired by Gilead; CEO and Chairman of InterMune, acquired by Roche and Chairman of Avexis, acquired by Novartis Mr. Welch currently serves as the Chairman of the Board or board director of several public and private biotech companies that are developing medicines and gene therapies to treat various forms of cancer, orphan diseases and diseases of the cardiovascular and metabolic system. He is also an advisor to biotech CEOs.

Mr. Welch holds a B.A. degree with honors from the University of Miami and M.B.A. degree from the University of North Carolina. He has published a novel, Race for the Mind in which the main characters are biotech CEOs.